B D Evans

978 total citations
24 papers, 728 citations indexed

About

B D Evans is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, B D Evans has authored 24 papers receiving a total of 728 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Pathology and Forensic Medicine and 5 papers in Molecular Biology. Recurrent topics in B D Evans's work include Cancer Treatment and Pharmacology (5 papers), Chemotherapy-induced organ toxicity mitigation (4 papers) and Chemotherapy-induced cardiotoxicity and mitigation (3 papers). B D Evans is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Chemotherapy-induced organ toxicity mitigation (4 papers) and Chemotherapy-induced cardiotoxicity and mitigation (3 papers). B D Evans collaborates with scholars based in New Zealand, United States and United Kingdom. B D Evans's co-authors include Ian E. Smith, S. J. Harland, V.J. Harvey, H.T. Ford, A H Calvert, John Yarnold, Bridget A. Robinson, E. Wiltshaw, Vilma D. Mottironi and Ulrich H. Rudofsky and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Life Sciences.

In The Last Decade

B D Evans

23 papers receiving 701 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B D Evans New Zealand 11 362 217 118 115 113 24 728
Jacob Colsky United States 16 449 1.2× 234 1.1× 104 0.9× 176 1.5× 92 0.8× 40 899
Carl G. Schmidt Germany 13 265 0.7× 349 1.6× 58 0.5× 84 0.7× 86 0.8× 33 798
Juhani Mäenpää Finland 17 201 0.6× 175 0.8× 68 0.6× 54 0.5× 63 0.6× 75 943
W.R. Bezwoda South Africa 16 367 1.0× 204 0.9× 71 0.6× 95 0.8× 99 0.9× 41 891
Florence Mishellany France 17 295 0.8× 195 0.9× 107 0.9× 105 0.9× 79 0.7× 37 811
Z Zawadzki United States 16 132 0.4× 257 1.2× 122 1.0× 62 0.5× 55 0.5× 39 846
Joo Han Lim South Korea 18 393 1.1× 335 1.5× 69 0.6× 144 1.3× 85 0.8× 61 867
B Unsgaard Sweden 15 408 1.1× 234 1.1× 265 2.2× 261 2.3× 79 0.7× 25 1.1k
Paul Thompson New Zealand 20 311 0.9× 376 1.7× 52 0.4× 165 1.4× 50 0.4× 44 1.1k
P Stiehl Germany 13 200 0.6× 304 1.4× 199 1.7× 102 0.9× 60 0.5× 25 986

Countries citing papers authored by B D Evans

Since Specialization
Citations

This map shows the geographic impact of B D Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B D Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B D Evans more than expected).

Fields of papers citing papers by B D Evans

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B D Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B D Evans. The network helps show where B D Evans may publish in the future.

Co-authorship network of co-authors of B D Evans

This figure shows the co-authorship network connecting the top 25 collaborators of B D Evans. A scholar is included among the top collaborators of B D Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B D Evans. B D Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Turney, J. H., et al.. (2025). Pirfenidone in Skin Fibrosis and Scarring: From Bench Insights to Clinical Data. Medical Sciences. 13(3). 148–148.
2.
Jameson, Michael B., Paul Thompson, Bruce C. Baguley, et al.. (2003). Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. British Journal of Cancer. 88(12). 1844–1850. 115 indexed citations
3.
Rongione, Anthony J., B D Evans, Karen Kling, & David W. McFadden. (1996). Ductography is a useful technique in evaluation of abnormal nipple discharge.. PubMed. 62(10). 785–8. 30 indexed citations
4.
Jameson, Michael B., B D Evans, Daniel H.D. Gray, et al.. (1995). Adjuvant chemotherapy for non‐metastatic osteosarcorna of the extremities in two New Zealand cancer centres. Australian and New Zealand Journal of Medicine. 25(3). 224–229. 2 indexed citations
5.
Anderson, Neil E., et al.. (1995). Paraneoplastic cerebellar degeneration in a patient with chemotherapy-responsive ovarian cancer. International Journal of Gynecological Cancer. 5(5). 396–399. 7 indexed citations
6.
Samuel, Leslie, V.J. Harvey, Paul Mitchell, et al.. (1994). Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. European Journal of Cancer. 30(14). 2054–2056. 7 indexed citations
7.
Rudofsky, Ulrich H., et al.. (1993). Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization.. PubMed. 68(4). 419–26. 99 indexed citations
8.
Mitchell, Paul, V.J. Harvey, M. R. Lane, et al.. (1993). Palliation of biliary obstruction in patients with advanced breast cancer using endoscopic stents. British journal of surgery. 80(9). 1188–1189. 1 indexed citations
9.
Mitchell, Paul, et al.. (1992). Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.. PubMed. 105(929). 73–5. 5 indexed citations
10.
Pérez, David, V.J. Harvey, Bridget A. Robinson, et al.. (1991). A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.. Journal of Clinical Oncology. 9(12). 2148–2152. 93 indexed citations
11.
McKeage, Mark J., B D Evans, Christopher M. Atkinson, et al.. (1990). Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group.. Journal of Clinical Oncology. 8(5). 779–783. 31 indexed citations
12.
Judson, Ian, A H Calvert, G. Abel, et al.. (1989). Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).. PubMed. 49(19). 5475–9. 10 indexed citations
13.
Coutts, J., et al.. (1988). Metastasizing Leiomyoma of the Uterus. Australian and New Zealand Journal of Obstetrics and Gynaecology. 28(2). 154–155. 8 indexed citations
14.
Smith, Ian E., B D Evans, M. Gore, et al.. (1987). Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer.. Journal of Clinical Oncology. 5(2). 185–189. 83 indexed citations
15.
Smith, Ian E., B D Evans, S. J. Harland, et al.. (1985). High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma. Cancer Chemotherapy and Pharmacology. 14(2). 120–124. 64 indexed citations
16.
Evans, B D, I. E. Smith, R D Clutterbuck, & Jeremy Millar. (1983). Normal tissue toxicity and antitumour experiments carried out in mice using high-dose cyclophosphamide. Cancer Treatment Reviews. 10. 25–32. 5 indexed citations
17.
Evans, B D, Ian E. Smith, & Jeremy Millar. (1983). High dose cyclophosphamide treatment of human oat cell xenografts in immune deprived mice. British Journal of Cancer. 47(2). 215–219. 4 indexed citations
18.
Evans, B D, Ian E. Smith, A. J. Shorthouse, & Jeremy Millar. (1982). A comparison of the response of human lung carcinoma xenografts to vindesine and vincristine. British Journal of Cancer. 45(3). 466–468. 13 indexed citations
19.
Vogel, Wolfgang & B D Evans. (1977). Structure-activity-relationships of certain hallucinogenic substances based on brain levels. Life Sciences. 20(10). 1629–1635. 18 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacob Colsky Breakdown of academic impact, for papers by Carl G. Schmidt Breakdown of academic impact, for papers by Juhani Mäenpää Breakdown of academic impact, for papers by W.R. Bezwoda Breakdown of academic impact, for papers by Florence Mishellany Breakdown of academic impact, for papers by Z Zawadzki Breakdown of academic impact, for papers by Joo Han Lim Breakdown of academic impact, for papers by B Unsgaard Breakdown of academic impact, for papers by Paul Thompson Breakdown of academic impact, for papers by P Stiehl
Rankless by CCL
2026